These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17238690)

  • 1. Adherence to dyslipidemia treatment guidelines in diabetic patients.
    Reichley R; McKinnon PS; Seaton T; Noirot L; Dunagan WC; Bailey TC
    AMIA Annu Symp Proc; 2006; 2006():1071. PubMed ID: 17238690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving adherence to dyslipidemia medication guidelines in hospitalized diabetic patients using a technology-assisted pharmacist intervention.
    McKinnon PS; Seaton T; Noirot LA; Reichley RM; Heard KM; Shannon WD; Goldberg AC; Dunagan WC; Bailey TC
    AMIA Annu Symp Proc; 2008 Nov; ():868. PubMed ID: 18999065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2019 May; 131(Suppl 1):136-138. PubMed ID: 30980157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia.
    Dake AW; Sora ND
    Am J Med Sci; 2016 Apr; 351(4):361-5. PubMed ID: 27079341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician adherence to the dyslipidemia guidelines is as challenging an issue as patient adherence.
    Vashitz G; Meyer J; Parmet Y; Henkin Y; Peleg R; Gilutz H
    Fam Pract; 2011 Oct; 28(5):524-31. PubMed ID: 21566005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids, lipid-lowering therapy and diabetes complications.
    Valensi P; Picard S
    Diabetes Metab; 2011 Feb; 37(1):15-24. PubMed ID: 21126902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 9. Pseudodyslipidemia: are we over-treating dyslipidemia in diabetic patients with undiagnosed gastroparesis?
    Adar T; Lysy J
    Endocrine; 2014 Feb; 45(1):26-7. PubMed ID: 24197805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in elderly diabetic patients.
    Verny C
    Diabetes Metab; 2005 Dec; 31 Spec No 2():5S74-5S81. PubMed ID: 16415769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006.
    Ahola TL; Jula AM; Kantola IM; Mäki J; Klaukka T; Reunanen A
    J Hypertens; 2009 Nov; 27(11):2283-93. PubMed ID: 19834341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term impact of modified blood-lipid reports on physicians' lipid lowering drug prescribing behavior and knowledge improvement on dyslipidemia].
    Li JH; Jiang H; Sun XH; Li CC; Ke YN; Yan SK; Wu YF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Apr; 40(4):318-22. PubMed ID: 22801311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MAURO study: baseline characteristics and compliance with guidelines targets.
    Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
    J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers.
    Mazzolini TA; Irons BK; Schell EC; Seifert CF
    J Manag Care Pharm; 2005; 11(9):763-71. PubMed ID: 16300420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 19. The burden and management of dyslipidemia: practical issues.
    Schultz AB; Chen CY; Burton WN; Edington DW
    Popul Health Manag; 2012 Oct; 15(5):302-8. PubMed ID: 22823455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):62-9. PubMed ID: 17924453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.